v3.26.1
Schedule of Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 19,311 $ 16,116
Capitalized research and experimental costs 5,708 7,836
Research and development credit carryforwards 1,945 1,945
Capitalized start-up expenses 117 135
Stock-based compensation 108 183
Other 660 309
Total deferred tax assets 27,849 26,524
Valuation allowance (27,849) (26,524)
Net deferred tax assets